Published in Cancer Chemother Pharmacol on May 29, 2010
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med (2007) 8.28
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest (2004) 2.73
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol (2011) 2.67
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol (2009) 2.31
Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol (2002) 2.27
Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev (2002) 2.26
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res (2005) 2.19
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol (2008) 2.18
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res (2006) 2.07
A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg (2015) 2.04
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol (2008) 1.97
RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene (2003) 1.95
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest (2005) 1.93
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine (2009) 1.93
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol (2007) 1.91
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.87
Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist (2006) 1.70
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res (2006) 1.68
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther (2005) 1.65
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol (2008) 1.61
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol (2007) 1.60
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med (2012) 1.60
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer (2007) 1.58
Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer (2010) 1.52
Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol (2010) 1.50
A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys (2005) 1.49
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Oncology (2011) 1.48
Malignant pleural mesothelioma: a comprehensive review. Cancer Control (2006) 1.47
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer (2010) 1.47
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer (2006) 1.47
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol (2006) 1.45
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. Haematologica (2002) 1.39
Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. Eur Urol (2006) 1.38
Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol (2003) 1.34
The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol (2007) 1.31
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother (2013) 1.30
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat (2007) 1.30
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat (2006) 1.29
Lung cancer. Practice organization. Chest (2003) 1.27
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.25
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol (2007) 1.25
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother (2010) 1.24
Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol (2004) 1.23
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. Genet Med (2008) 1.23
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol (2011) 1.23
Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res (2011) 1.19
Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol (2007) 1.19
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 1.18
Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain (2009) 1.18
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer (2009) 1.17
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol (2008) 1.17
Can patient selection for bladder preservation be based on response to chemotherapy? Cancer (2003) 1.16
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology (2005) 1.15